EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access

Pilot Study of Combining Stereotactic Body Radiation Therapy with Pulsed Field Ablation for Oligometastatic/Oligoprogressive Lung Tumors

Jeremy P Harris, Christina Boyd, Mengying Shi, Michael Reilly, Aaron Simon, Steven N Seyedin, Wen-Pin Chen, Misako Nagasaka, Rupali Nabar, Nadine Abi-Jaoudeh

Journal of Vascular and Interventional Radiology · 2025

DOI: 10.1016/j.jvir.2025.08.005 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Journal of Vascular and Interventional Radiology, 2025. Verfasst von Jeremy P Harris und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of California-Irvine, Orange, California. Electronic address: Jpharris1@uci.edu. Hauptthemen laut MEDLINE: Radiosurgery, Lung Neoplasms, Ablation Techniques. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, University of California Irvine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To evaluate the feasibility of combining pulsed field ablation through irreversible electroporation (IRE) or pulsed electric field (PEF) with stereotactic body radiation therapy (SBRT) delivered within 15 days for lung tumors. MATERIALS AND METHODS: A prospective pilot study was designed for the treatment of lung tumors with pulsed field ablation followed by 12 Gy in 1 fraction. Percutaneous ablation via paired electrode probes (IRE) or a single-probe system (PEF) was allowed on the trial; the intent was complete ablation. Patients with oligometastatic or oligoprogressive cancer of any histology and 1-3 lung tumor targets of 1-6 cm were included. The primary end point was feasibility, while secondary end points were safety, local failure, progression-free survival, overall survival, and changes in lung function. This trial was registered with ClinicalTrials.gov (NCT05555342). RESULTS: Six patients with 8 tumors were enrolled and treated, including 3 ultracentral, 2 central, and 3 peripheral tumors. All patients completed treatment with PEF ablation (n = 0 with IRE) and SBRT, and 1 had a Grade ≥3 adverse event related to postprocedural extubation. Other adverse events were of Grade 1 (n = 3). There were no significant changes from baseline to 3 months in forced vital capacity (FVC, P = .68), forced expiratory volume in 1 second (FEV1, P = .16), or diffusing capacity of the lung for carbon monoxide (DLCO, P = .30). The median follow-up was 19 months, and there were 3 local failures in 2 patients. The 12-month rate of local failure was 37.5% (95% CI, 7%-69%), progression-free survival was 17% (95% CI, 3%-99%), and overall survival was 83% (95% CI, 58%-100%). CONCLUSIONS: Combining pulsed field ablation in this pilot trial was feasible and well-tolerated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiosurgeryLung NeoplasmsAblation TechniquesHumansPilot ProjectsFemaleProspective StudiesMaleAgedFeasibility StudiesMiddle AgedProgression-Free SurvivalAged, 80 and overTime FactorsTreatment OutcomeDisease ProgressionElectroporationTumor Burden

Autor:innen und Institutionen

  • Department of Radiation Oncology, University of California-Irvine, Orange, California. Electronic address: Jpharris1@uci.edu.
  • Division of Vascular & Interventional Radiology, University of California-Irvine, Orange, California.
  • Department of Radiation Oncology, University of California-Irvine, Orange, California.
  • Department of Radiation Oncology, University of California-San Francisco, San Francisco, California.
  • Department of Medicine, University of California-Irvine, Orange, California.
  • Division of Hematology & Oncology, University of California-Irvine, Orange, California.

Förderung

  • NCI NIH HHS
  • University of California Irvine

Zitieren

APA

Harris, J. P., Boyd, C., Shi, M., Reilly, M., Simon, A., Seyedin, S. N., Chen, W. P., Nagasaka, M., Nabar, R., & Abi-Jaoudeh, N. (2025). Pilot Study of Combining Stereotactic Body Radiation Therapy with Pulsed Field Ablation for Oligometastatic/Oligoprogressive Lung Tumors. Journal of Vascular and Interventional Radiology. https://doi.org/10.1016/j.jvir.2025.08.005

Vancouver

Harris JP, Boyd C, Shi M, Reilly M, Simon A, Seyedin SN, et al. Pilot Study of Combining Stereotactic Body Radiation Therapy with Pulsed Field Ablation for Oligometastatic/Oligoprogressive Lung Tumors. Journal of Vascular and Interventional Radiology. 2025. doi:10.1016/j.jvir.2025.08.005

BibTeX
@article{Harris2025,
  author = {Harris, Jeremy P and Boyd, Christina and Shi, Mengying and Reilly, Michael and Simon, Aaron and Seyedin, Steven N and Chen, Wen-Pin and Nagasaka, Misako and Nabar, Rupali and Abi-Jaoudeh, Nadine},
  title = {Pilot Study of Combining Stereotactic Body Radiation Therapy with Pulsed Field Ablation for Oligometastatic/Oligoprogressive Lung Tumors},
  journal = {Journal of Vascular and Interventional Radiology},
  year = {2025},
  doi = {10.1016/j.jvir.2025.08.005}
}
Kostenlos starten →